{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:13:09Z","timestamp":1761894789283},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,10,25]],"date-time":"2008-10-25T00:00:00Z","timestamp":1224892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2008,10,25]],"date-time":"2008-10-25T00:00:00Z","timestamp":1224892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s10637-008-9191-7","type":"journal-article","created":{"date-parts":[[2008,10,24]],"date-time":"2008-10-24T03:32:36Z","timestamp":1224819156000},"page":"476-481","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma"],"prefix":"10.1007","volume":"27","author":[{"given":"Lawrence E.","family":"Garbo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret A.","family":"MacRae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary A.","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn S.","family":"Kolibaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,25]]},"reference":[{"issue":"2","key":"9191_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/modpathol.3880035","volume":"13","author":"NL Harris","year":"2000","unstructured":"Harris NL, Jaffe ES, Diebold J et al (2000) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13(2):193\u2013207 doi:10.1038\/modpathol.3880035","journal-title":"Mod Pathol"},{"key":"9191_CR2","unstructured":"Jaffe E, Harris N, Stein H, Vardiman JW (eds) (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, France"},{"issue":"2","key":"9191_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1046\/j.1365-2141.2003.04761.x","volume":"124","author":"F Bertoni","year":"2004","unstructured":"Bertoni F, Zucca E, Cotter FE (2004) Molecular basis of mantle cell lymphoma. Br J Haematol 124(2):130\u2013140 doi:10.1046\/j.1365-2141.2003.04761.x","journal-title":"Br J Haematol"},{"issue":"6","key":"9191_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1470-2045(04)01490-1","volume":"5","author":"BT Hennessy","year":"2004","unstructured":"Hennessy BT, Hanrahan EO, Daly PA (2004) Non-Hodgkin lymphoma: an update. Lancet Oncol 5(6):341\u2013353 doi:10.1016\/S1470-2045(04)01490-1","journal-title":"Lancet Oncol"},{"issue":"9","key":"9191_CR5","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E et al (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23(9):1984\u20131992 doi:10.1200\/JCO.2005.08.133","journal-title":"J Clin Oncol"},{"key":"9191_CR6","unstructured":"National Comprehensive Cancer Network (NCCN) NCCN Clinical practice guidelines in oncology: Non-hodgkin\u2019s lymphoma, v.2.2008. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/nhl.pdf"},{"key":"9191_CR7","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Non-hodgkin\u2019s lymphoma, v.1.2005 (effective 6\/21\/05)."},{"key":"9191_CR8","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1200\/JCO.1999.17.12.3786","volume":"17","author":"A Fossa","year":"1999","unstructured":"Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, Bonadonna G, Seeber S, Nowrousian MR (1999) Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol 17:3786\u20133792","journal-title":"J Clin Oncol"},{"key":"9191_CR9","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","volume":"18","author":"A Santoro","year":"2000","unstructured":"Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V (2000) Gemcitabine in the treatment of refractory Hodgkin\u2019s disease: results of a multicenter phase II study. J Clin Oncol 18:2615\u20132619","journal-title":"J Clin Oncol"},{"key":"9191_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1023\/A:1008307528519","volume":"11","author":"DG Savage","year":"2000","unstructured":"Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, Ruiz J, Heitjan D, Keohan ML, Flamm M, Johnson SA (2000) Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 11:595\u2013597 doi:10.1023\/A:1008307528519","journal-title":"Ann Oncol"},{"issue":"3","key":"9191_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","volume":"113","author":"C Dumontet","year":"2001","unstructured":"Dumontet C, Morschhauser F, Solal-Celigny P et al (2001) Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin\u2019s lymphoma. Br J Haematol 113(3):772\u2013778 doi:10.1046\/j.1365-2141.2001.02795.x","journal-title":"Br J Haematol"},{"key":"9191_CR12","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"D Maloney","year":"1997","unstructured":"Maloney D, Grillo-L\u00f3pez A, White C et al (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"issue":"6","key":"9191_CR13","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N et al (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92(6):1927\u20131932","journal-title":"Blood"},{"issue":"2","key":"9191_CR14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZ, Cunningham D et al (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18(2):317\u2013324","journal-title":"J Clin Oncol"},{"issue":"2","key":"9191_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00174174","volume":"3","author":"RA Gams","year":"1985","unstructured":"Gams RA, Bryan S, Dukart G et al (1985) Mitoxantrone in malignant lymphoma. Invest New Drugs 3(2):219\u2013222 doi:10.1007\/BF00174174","journal-title":"Invest New Drugs"},{"issue":"10","key":"9191_CR16","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Fortstpointner","year":"2004","unstructured":"Fortstpointner R, Dreyling M, Repp R et al (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104(10):3064\u20133071 doi:10.1182\/blood-2004-04-1323","journal-title":"Blood"},{"issue":"1","key":"9191_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/10428190400007540","volume":"46","author":"C Wenger","year":"2005","unstructured":"Wenger C, Stern M, Herrmann R et al (2005) Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non-Hodgkin\u2019s lymphoma? Leuk Lymphoma 46(1):71\u201375 doi:10.1080\/10428190400007540","journal-title":"Leuk Lymphoma"},{"key":"9191_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216 doi:10.1093\/jnci\/92.3.205","journal-title":"J Natl Cancer Inst"},{"key":"9191_CR19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. JASA 53:457\u2013481","journal-title":"JASA"},{"issue":"3","key":"9191_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1517\/14796694.1.3.297","volume":"1","author":"C Traull\u00e9","year":"2005","unstructured":"Traull\u00e9 C, Coiffier BB (2005) Evolving role of rituximab in the treatment of patients with non-Hodgkin\u2019s lymphoma. Future Oncol 1(3):297\u2013306 doi:10.1517\/14796694.1.3.297","journal-title":"Future Oncol"},{"issue":"3","key":"9191_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.critrevonc.2005.10.001","volume":"58","author":"J Brody","year":"2006","unstructured":"Brody J, Advani R (2006) Treatment of mantle cell lymphoma: current approach and future directions. Crit Rev Oncol Hematol 58(3):257\u2013265 doi:10.1016\/j.critrevonc.2005.10.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"9191_CR22","first-page":"CD003805","volume":"4","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius J, Skoetz N et al (2007) Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma. Cochrane Database Syst Rev 4:CD003805","journal-title":"Cochrane Database Syst Rev"},{"key":"9191_CR23","unstructured":"National Cancer Institute FDA Approval for Bortezomib. http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-bortezomib (accessed February 12, 2008)"},{"issue":"4","key":"9191_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P et al (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 23(4):667\u2013675 doi:10.1200\/JCO.2005.03.108","journal-title":"J Clin Oncol"},{"issue":"4","key":"9191_CR25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA, Wright J, Moskowitz C et al (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol 23(4):676\u2013684 doi:10.1200\/JCO.2005.02.050","journal-title":"J Clin Oncol"},{"issue":"18 Pt 1","key":"9191_CR26","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","volume":"13","author":"RC Kane","year":"2007","unstructured":"Kane RC, Dagher R, Farrell A et al (2007) Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13(18 Pt 1):5291\u20135294 doi:10.1158\/1078-0432.CCR-07-0871","journal-title":"Clin Cancer Res"},{"issue":"8","key":"9191_CR27","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1080\/07357900701579570","volume":"25","author":"P Barr","year":"2007","unstructured":"Barr P, Fisher R, Friedberg J (2007) The role of bortezomib in the treatment of lymphomas. Cancer Invest 25(8):766\u2013775 doi:10.1080\/07357900701579570","journal-title":"Cancer Invest"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-008-9191-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-008-9191-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-008-9191-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-008-9191-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:39:04Z","timestamp":1678559944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-008-9191-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,25]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["9191"],"URL":"https:\/\/doi.org\/10.1007\/s10637-008-9191-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,25]]},"assertion":[{"value":"14 July 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}